Invion Limited (@invionlimited) 's Twitter Profile
Invion Limited

@invionlimited

Clinical stage company developing the next-gen Photodynamic Therapy (PDT), called Photosoft, for the treatment of a range of cancers & infectious diseases

ID: 1016297240

linkhttp://inviongroup.com calendar_today16-12-2012 23:32:15

175 Tweet

179 Followers

128 Following

Invion Limited (@invionlimited) 's Twitter Profile Photo

.Invion Limited & the Hudson Institute, have announced significant in vitro data for the new IVXP02 PhotosoftTM formulation, including a validated at 15x potency compared to other PDT treatments for ovarian cancer cells. See more here - youtu.be/dbvDMAr4DXQ #IVX #ASX #ausbio

Invion Limited (@invionlimited) 's Twitter Profile Photo

Invion's (ASX: IVX) CEO Thian Chew speaks with 180 Markets about what makes Invion's next-gen PDT technology so unique as a potential cancer treatment 180 Markets #markets #health #healthtech #cancer #asxnews #biotech youtube.com/watch?v=dn24VX…

Invion Limited (@invionlimited) 's Twitter Profile Photo

Invion eyes multiple applications and new markets for next-generation photodynamic therapy #investments #ASX #biotech #Covid_19 #shares #stocks smallcaps.com.au/invion-group-e…

Small Caps (@smallcapsasx) 's Twitter Profile Photo

Invion’s (#ASX: $IVX) INV043 candidate demonstrates positive results in Phase II prostate cancer trial. smallcaps.com.au/invion-inv043-… Invion Limited

Invion Limited (@invionlimited) 's Twitter Profile Photo

Results from Ph 2 prostate cancer trial using INV043 showed it to be safe & well tolerated by patients, 40% showed a positive response using RECIST 1.1 (10% complete regression) & 44% negative on PSMA-PET. investors.inviongroup.com/announcements/… #asx #smallcaps #CancerResearch #investing

Results from Ph 2  prostate cancer trial using INV043 showed it to be safe & well tolerated by patients, 40% showed a  positive response using RECIST 1.1 (10% complete regression) & 44% negative on PSMA-PET. investors.inviongroup.com/announcements/… #asx #smallcaps #CancerResearch #investing
Invion Limited (@invionlimited) 's Twitter Profile Photo

Webinar where Invion's CEO, Thian Chew, spoke about the successful Ph 2 prostate cancer results, the Ph 1/2 skin cancer trial and what these mean for Invion in the near-term. youtube.com/watch?v=QttqRD… #investing #investments #cancerresearch #ASX #stockstowatch #smallcaps #biotech

Invion Limited (@invionlimited) 's Twitter Profile Photo

Following our positive Phase 2 Prostate Cancer Trial results, many have asked how Photosoft works. This 1 minute animation explains the mechanism of action #CancerResearch #ASX #biotech #StocksInFocus #Stocks #stockinvesting #SmallCaps

Brendon Lau (@brenlau) 's Twitter Profile Photo

Solid safety data from Invion Limited's Ph2 prostate cancer trial very encouraging vs potential side effects from radiotherapy/surgery (urinary incontinence, bowel & erectile dysfunction, infertility) investors.inviongroup.com/announcements/… #CancerResearch #Oncology #smallcap #StocksInFocus

Solid safety data from <a href="/InvionLimited/">Invion Limited</a>'s  Ph2 prostate cancer trial very encouraging vs potential side effects from radiotherapy/surgery (urinary  incontinence, bowel &amp; erectile dysfunction, infertility) investors.inviongroup.com/announcements/… #CancerResearch #Oncology #smallcap #StocksInFocus
Invion Limited (@invionlimited) 's Twitter Profile Photo

We are excited to be profiled by Stockhead in The Australian with the publication showcasing our promising Photosoft technology in fighting cancers. Click here to read more theaustralian.com.au/business/stock… #stockstofocus #ASX #Biotechnology #investing #Oncology #CancerResearch

We are excited to be profiled by Stockhead in The Australian with the publication showcasing our promising Photosoft technology in fighting cancers. Click here to read more theaustralian.com.au/business/stock… #stockstofocus #ASX #Biotechnology #investing #Oncology #CancerResearch